Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options

Area of Science:

• Nephrology
• Immunology
• Genetics

Background:

• Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are kidney diseases caused by dysregulation of the alternative complement pathway.
• Genetic factors affecting complement regulatory proteins and environmental triggers contribute to disease development.
• Historically, these conditions had poor prognoses, often leading to end-stage renal disease and graft loss after transplantation.

Purpose of the Study:

• To review the pathophysiology of aHUS and C3G related to complement dysregulation.
• To highlight the historical poor outcomes associated with these diseases.
• To discuss the impact of recent advances in complement inhibitor therapies.

Main Methods:

• Literature review of complement-mediated kidney diseases.
• Analysis of genetic factors and clinical triggers.
• Evaluation of treatment outcomes with complement inhibitors.

Main Results:

• Inappropriate alternative complement pathway activation is central to aHUS and C3G.
• Targeted complement inhibition has led to improved disease remission and renal recovery.
• Allograft survival in renal transplantation has significantly improved with new therapies.

Conclusions:

• Targeted complement inhibitor therapy represents a paradigm shift in managing aHUS and C3G.
• These therapies offer improved quality of life and better long-term outcomes for patients.
• Further research into complement pathways may yield additional therapeutic strategies.